Skip to main content
Log in

Therapie immunkompetenter Patienten

Addition von Cetuximab zur Radiochemotherapie von Analkarzinomen

  • journal club
  • Published:
InFo Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. James RD et al. Lancet Oncol. 2013;14(6):516–24.

    Article  CAS  PubMed  Google Scholar 

  2. Garg MK et al. J Clin Oncol. 2017;35(7):718–726.

    Article  PubMed  Google Scholar 

  3. Gunderson LL et al. J Clin Oncol. 2012;30(35):4344–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Glynne-Jones R et al. Lancet Oncol. 2017;18(3):347–356.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Doll CM et al. Int J Radiat Oncol Biol Phys. 2017;97(3):554–562.

    Article  CAS  PubMed  Google Scholar 

  6. Yates A et al. Clin Oncol (R Coll Radiol). 2015;27(12):700–7.

    Article  CAS  Google Scholar 

Originalie

  • Garg MK. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol. 2017;35(7):718–26.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carsten Nieder.

Additional information

Erstpubliziert in Strahlenther Onkol. 2017;193(6):508-9.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nieder, C. Addition von Cetuximab zur Radiochemotherapie von Analkarzinomen. Info Onkol. 20, 16–17 (2017). https://doi.org/10.1007/s15004-017-5843-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-017-5843-0

Schlüsselwörter

Navigation